TW202140770A - 高活性nk細胞之處理方法 - Google Patents

高活性nk細胞之處理方法 Download PDF

Info

Publication number
TW202140770A
TW202140770A TW110107331A TW110107331A TW202140770A TW 202140770 A TW202140770 A TW 202140770A TW 110107331 A TW110107331 A TW 110107331A TW 110107331 A TW110107331 A TW 110107331A TW 202140770 A TW202140770 A TW 202140770A
Authority
TW
Taiwan
Prior art keywords
cells
hours
thawing
kbm
hour
Prior art date
Application number
TW110107331A
Other languages
English (en)
Chinese (zh)
Inventor
原田結
米満吉和
Original Assignee
日商蓋亞生物製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商蓋亞生物製藥有限公司 filed Critical 日商蓋亞生物製藥有限公司
Publication of TW202140770A publication Critical patent/TW202140770A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW110107331A 2020-03-02 2021-03-02 高活性nk細胞之處理方法 TW202140770A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-035297 2020-03-02
JP2020035297A JP7793284B2 (ja) 2020-03-02 2020-03-02 高活性ｎｋ細胞の処理方法

Publications (1)

Publication Number Publication Date
TW202140770A true TW202140770A (zh) 2021-11-01

Family

ID=77614337

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110107331A TW202140770A (zh) 2020-03-02 2021-03-02 高活性nk細胞之處理方法

Country Status (8)

Country Link
US (1) US20230109717A1 (https=)
EP (1) EP4151717A4 (https=)
JP (2) JP7793284B2 (https=)
KR (1) KR20220148233A (https=)
CN (1) CN115279887A (https=)
AU (1) AU2021230860A1 (https=)
TW (1) TW202140770A (https=)
WO (1) WO2021177279A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
EP4582545A1 (en) 2022-08-30 2025-07-09 GAIA BioMedicine Inc. Monobody and nk cells
AU2024234571A1 (en) 2023-03-15 2025-09-25 Gaia Biomedicine Inc. Solution for suspending cells and use thereof
KR102940135B1 (ko) 2024-01-05 2026-03-16 인하대학교 산학협력단 고삼투 및 진동 자극에 노출된 배양보조세포를 통한 nk 세포의 효과적인 활성화 및 이의 용도
CN121294344A (zh) * 2024-06-20 2026-01-09 杭州百瑞竞康生物技术有限公司 Nk细胞无血清培养基

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4385158B2 (ja) * 2000-12-04 2009-12-16 株式会社リンフォテック 細胞の保存液および該保存液を用いた細胞の保存方法
JP4947948B2 (ja) 2004-10-12 2012-06-06 ニプロ株式会社 細胞保存液
US20120149108A1 (en) 2009-08-19 2012-06-14 Masashige Tanabe Cell preservation method
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
EP2925861B1 (en) 2012-11-29 2018-09-05 Takara Bio Europe AB Improved methods for producing mammalian pluripotent stem cell-derived endodermal cells
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
MY201637A (en) * 2015-10-15 2024-03-06 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
WO2018017843A1 (en) * 2016-07-22 2018-01-25 Tissue Testing Technologies Llc Enhancement of cell cryopreservation with glycolipids
JP7398959B2 (ja) 2017-05-04 2023-12-15 メゾブラスト・インターナショナル・エスアーエールエル 向上した免疫抑制作用を有する間葉系前駆または幹細胞
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
JP2019024418A (ja) 2017-07-31 2019-02-21 公立大学法人大阪府立大学 選択分離用培地
JP6543375B1 (ja) 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基

Also Published As

Publication number Publication date
JP2023126695A (ja) 2023-09-07
JP7793284B2 (ja) 2026-01-05
JP2021136883A (ja) 2021-09-16
KR20220148233A (ko) 2022-11-04
WO2021177279A1 (ja) 2021-09-10
CN115279887A (zh) 2022-11-01
US20230109717A1 (en) 2023-04-13
EP4151717A1 (en) 2023-03-22
EP4151717A4 (en) 2024-04-17
AU2021230860A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
TW202140770A (zh) 高活性nk細胞之處理方法
Chinnadurai et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing
TWI640629B (zh) Mammalian cell transplantation solution containing trehalose and polyglucose
CN103210903B (zh) 一种用于保存cik细胞的冻存液及其应用
KR102784950B1 (ko) 포유동물 세포의 보존액
JP7144872B2 (ja) ヒトリンパ球細胞培養用無血清培地
JPWO2014208100A1 (ja) 間葉系細胞を利用した巨核球、血小板及び／又はトロンボポエチンの製造方法
CA2955445A1 (en) Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
JP2009219376A (ja) 医療用細胞の保護用液
CN105963699A (zh) Fats作为黑色素瘤免疫治疗的靶点及应用
EP4400576A1 (en) Method for treating cells
HK40084673A (en) Method for treating highly active nk cells
US20240277767A1 (en) Methods and uses
KR20250161543A (ko) 세포를 현탁하기 위한 액 및 그 이용
HK40083554A (en) Method for treating highly active nk cells
HK40106614A (zh) 细胞的处理方法
JP2013081428A (ja) Ｃｄ５６陽性ｔ細胞増強方法
HK40108875A (en) Method for treating cells
藤田泰毅 et al. Study on preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
Kaushal The impact of cryopreservation on the function of hematopoietic stem and progenitor cells
Ki Characterisation of dendritic cell immune profile in models of transfusion
EP3750988A1 (en) Improved alpha beta t processed cell production method
CN119970755A (zh) 一种蟾毒配基类组合物及其制剂和应用
Al-Azzawi A role for the human mesenchymal stem cell secretome in attenuation of cytokine-induced apoptosis in pancreatic beta cells
McFarland et al. ASH 2010 meeting report—Top 10 clinically oriented abstracts in transfusion medicine